Day: September 25, 2024

JENA, Germany, Sept. 25, 2024 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the e-poster presentation of a post hoc analysis of the SHINE Phase 2b study of its first-in-class anti-C5a antibody, vilobelimab, in hidradenitis suppurativa (HS) at the 2024 European Academy of Dermatology and Venereology (EADV) Congress being held in Amsterdam, September 25 – 28, 2024. Camilla Chong, MD, Chief Medical Officer of InflaRx, commented: “This analysis sheds significant light on the role of C5a/C5aR signaling and vilobelimab’s ability to address the underlying inflammation driving hidradenitis suppurativa (HS), including its potential to reduce not only abscesses and nodules, but draining tunnels that remain a significant...

BATON ROUGE, La., Sept. 25, 2024 (GLOBE NEWSWIRE) — Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care in the home, has 92 home health and hospice care centers recognized by Strategic Healthcare Programs (SHP) for achieving the highest overall HHCAHPS patient satisfaction or CAHPS Hospice caregiver satisfaction scores of all eligible SHP clients in 2023. This includes 14 care centers awarded Premier Performer, ranking in the top 5%, and 78 care centers awarded Superior Performer, ranking in the top 20%. Thirteen care centers achieved an award in each of the last 5 years of the SHPBest program. “Nothing we do is possible without our incredible caregivers delivering outstanding care in the home each and every day,” stated Scott Ginn, Chief Operating Officer and Chief Financial Officer,...

Provides 23andMe+ Premium members with insight into their likelihood of experiencing emotional eating based on their genetics SUNNYVALE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co., (Nasdaq: ME), a leading human genetics and preventive health company, today released a new report on the genetics of emotional eating for 23andMe+ Premium members, informing them if they are at a higher likelihood of frequent emotional eating. Emotional eating occurs when an individual frequently eats to cope with difficult feelings1. It often involves eating high-calorie, unhealthy foods, despite not feeling physically hungry, and can result in overeating. Emotional hunger is not satiated by food in the same way that physical hunger is, so while emotional eating may feel good in the moment, it can cause physical discomfort and feelings...

BEDFORD, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it will participate in the UBS Virtual Opthalmology Day 2024: UBS Virtual Opthalmology Day 2024Fireside Chat Date: Wednesday, October 2, 2024Presentation Time: 3:00 PM ETOcular Presenter: Pravin U. Dugel, MD, Executive Chairman, President and Chief Executive OfficerLocation: Virtual In addition to the fireside chat, Ocular leadership will host investor meetings at the conference. A live webcast of the fireside chat can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com. About Ocular Therapeutix, Inc.Ocular...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Sept. 25, 2024 (GLOBE NEWSWIRE) — Hampton Financial Corporation (“Hampton” or the “Company”, TSXV:HFC) is pleased to announce the appointment of John Levac, as CEO of Oxygen Working Capital Corp. (“Oxygen”), a wholly owned subsidiary of Hampton. “As we continue to develop and expand the scale of our newly acquired factoring business, Oxygen Working Capital Corp., we are delighted to welcome John Levac as CEO of Oxygen. John brings decades of experience in asset-backed and securitized lending to the company, having worked previously with major players in this space such as Wells Fargo & RBC. He also brings along numerous industry, lender and borrower relationships and we are pleased to have him join the team,” said Hampton Executive...

Conference Call and Webcast to be held on September 25, 2024 at 5:00 PM ET MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) — LuxUrban Hotels Inc. (“LuxUrban” or the “Company”) (Nasdaq: LUXH), which secures long-term operating rights for entire hotels through Master Lease Agreements (MLA) under which it manages the hotel and rents out, on a short-term basis, rooms to business and vacation travelers, will host a webcast to review the results of the 2nd quarter of 2024 on September 25th, 2024 at 5:00PM ET. The webcast will feature an overview of the quarter from Robert Arigo, CEO, and Mike James, CFO. To register for the event, please click HERE. Conference Call & Webcast Information:Time & Date: September 25, 2024, at 5:00PM ET PARTICIPANT DIAL IN (TOLL FREE): 1-877-317-6789 PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-6789 Webcast...

Data Readout Expected Early Calendar 2025; NDA Submission on Track for 1H Calendar 2025 PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that patient enrollment has been completed in the Company’s Phase 3 STRIVE-ON safety trial (the STRIVE-ON trial–NCT05995405). The STRIVE-ON trial is a prospective, open-label, randomized (1:1 ratio), parallel group trial of GTX-104 compared with oral nimodipine, in 100 patients hospitalized for aSAH. Approximately 25 hospitals in the U.S. are participating. “We are excited to announce the completion of enrollment in our...